Colin Rutherford has served as a member of Evofem Biosciences’ board of directors since 2017. He is an experienced public and private company chairman and independent director, with relevant sector experience including asset management, bioscience, leisure, and real estate.
In addition to Evofem, Mr. Rutherford currently serves on the boards of directors of several firms. He is Board Chair of Brookgate Limited (real estate development) and Rothley Group Limited, (private client legal services and claims management); Board member, Audit Committee Chair and SID-elect of New River REIT Plc, (LSE: NRR); and, Board member and Audit Committee Chair at Donaldson Group Limited (manufacturing). He also co-founded and has served as Chair of Act Blade Limited (wind energy blade manufacturing) since 2015, and since 2021 has been Chair of Allstone Group Limited (aggregates and waste recycling).
Mr. Rutherford previously served on the board of directors of companies including Hifas da Terra SA, a Spanish biopharma company; Meallmore Limited, a UK healthcare group; Right Group Limited, a recently-sold MIS/MPS distributor; Euro-Sales Plc, (sold to Royal Bank of Scotland); and, European Health Care Group (sold to two US-based hedge funds).
Early in his career, Mr. Rutherford co-founded Rutherford Manson Dowds (RMD), a UK corporate finance and full service accountancy firm. The firm was sold to Deloitte in 1999.
Mr. Rutherford earned a degree in Accountancy and Finance from Heriot Watt University, qualified with Touche Ross (now Deloitte) in 1984, and is a Harvard Business School alumnus. He is a Member of the Scottish Institute of Chartered Accountants.